

 **9 April 2024**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**for**

**Dorzolamid "Hexal", eye drops, solution**

**0. D.SP.NO.**

31328

**1. NAME OF THE MEDICINAL PRODUCT**

Dorzolamid "Hexal"

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains 20 mg dorzolamide (as dorzolamide hydrochloride).

Excipients with known effect

Each ml of solution contains 0.075 mg benzalkonium chloride.

For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Eye drops, solution

Clear, slightly viscous, colourless aqueous solution.

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Dorzolamid "Hexal" is indicated:

* as adjunctive therapy to beta-blockers,
* as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated,

In the treatment of elevated intra-ocular pressure in:

* ocular hypertension,
* open-angle glaucoma,
* pseudoexfoliative glaucoma.

**4.2 Posology and method of administration**

Posology

When used as monotherapy, the dose is one drop of Dorzolamid "Hexal" in the conjunctival sac of the affected eye(s), three times daily.

When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of Dorzolamid "Hexal" in the conjunctival sac of the affected eye(s), two times daily.

When substituting Dorzolamid "Hexal" for another ophthalmic anti-glaucoma agent, the other agent should be discontinued after proper dosing on one day, and dosing of Dorzolamid "Hexal" should be started on the next day.

Paediatric use

The experience in children is limited. Limited clinical data in paediatric patients with administration of dorzolamide three times a day are available. (For information regarding paediatric dosing see section 5.1).

Method of administration

If more than one topical ophthalmic medicinal product is being used, the medicinal products should be administered at least ten minutes apart.

Patients should be instructed to wash their hands before use and avoid allowing the tip of the container to come into contact with the eye or surrounding structures.

Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients should be informed of the correct handling of Dorzolamid "Hexal". If they have difficulty administering their eye drops, they should seek the assistance of a family member or carer.

When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.

Usage instructions

The patient should follow these instructions carefully when using Dorzolamid "Hexal". Before putting in the eye drops the patient should wash the hands.

1. The tamper-proof seal on the bottleneck must be unbroken before the product is being used for the first time.
2. The cap of the bottle should be unscrewed by turning it until the tamper-proof seal breaks.
3. The patient’s head must be tilted back and the lower eyelid must be pulled gently down to form a pocket between the eyelid and the eye.



1. The bottle should be inverted and squeezed until a single drop is dispensed into the eye. THE EYE OR EYELID MUST NOT BE TOUCHED WITH THE TIP OF THE CONTAINER.

 

1. Steps 3 and 4 should be repeated with the other eye if necessary.
2. The bottle should be reclosed by turning the cap firmly immediately after use and returned to the original outer carton.
3. The dispenser tip is designed to provide a pre-measured drop; therefore, the hole of the dispenser tip must not be enlarged.

**4.3 Contraindications**

Hypersensitivity to the active substance, sulphonamides or to any of the excipients listed in section 6.1.

Dorzolamide has not been studied in patients with severe renal impairment (CrCl < 30 ml/min) or with hyperchloraemic acidosis. Because dorzolamide and its metabolites are excreted predominantly by the kidneys, dorzolamide is therefore contraindicated in such patients.

**4.4 Special warnings and precautions for use**

Dorzolamide has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.

The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide has not been studied in patients with acute angle- closure glaucoma.

Dorzolamide is a sulphonamide and although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulphonamides may occur with topical administration, including severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. If signs of serious reactions of hypersensitivity occur, discontinue the use of this preparation.

Therapy with oral carbonic anhydrase inhibitors has been associated with urolithiasis as a result of acid-base disturbances, especially in patients with a prior history of renal calculi. Although no acid- base disturbances have been observed with dorzolamide, urolithiasis has been reported infrequently. Because dorzolamide is a topical carbonic anhydrase inhibitor that is absorbed systemically, patients with a prior history of renal calculi may be at increased risk of urolithiasis while using dorzolamide.

There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide. The concomitant administration of dorzolamide and oral carbonic anhydrase inhibitors is not recommended.

If allergic reactions (e.g. conjunctivitis and eyelid reactions) are observed, discontinuation of treatment should be considered.

Corneal oedemas and irreversible corneal decompensations have been reported in patients with pre-existing chronic corneal defects and/or a history of intraocular surgery while using dorzolamide.

Topical dorzolamide should be used with caution in such patients.

Choroidal detachment concomitant with ocular hypotony have been reported after filtration procedures with administration of aqueous suppressant therapies.

Dorzolamid "Hexal" contains the preservative benzalkonium chloride

This medicinal product contains 0.075 mg benzalkonium chloride in each ml. Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Should be used with caution in dry eye patients and in patients where the cornea may be compromised. Patients should be monitored in case of prolonged use.

Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. Contact lenses should be removed before using this medicinal product and put them back 15 minutes afterwards.

Paediatric population

Dorzolamide has not been studied in patients less than 36 weeks gestational age and less than one week of age. Patients with significant renal tubular immaturity should only receive dorzolamide after careful consideration of the risk benefit balance because of the possible risk of metabolic acidosis.

**4.5 Interaction with other medicinal products and other forms of interaction**

No interaction studies have been performed with dorzolamide.

In clinical studies, dorzolamide was used concomitantly with the following medicinal products without evidence of adverse interactions: timolol ophthalmic solution, betaxolol ophthalmic solution and systemic medicinal products, including ACE-inhibitors, calcium-channel blockers, diuretics, non-steroidal anti-inflammatory drugs including acetylsalicylic acid, and hormones (e.g. oestrogen, insulin, thyroxine).

Association between dorzolamide and miotics and adrenergic agonists has not been fully evaluated during glaucoma therapy.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

Dorzolamide should not be used during pregnancy. There are no or limited amount of data from the use of dorzolamide in pregnant women. In rabbits, dorzolamide produced teratogenic effects at maternotoxic doses (see section 5.3).

Breast-feeding

It is unknown whether dorzolamide/metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of dorzolamide/metabolites in milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from dorzolamide therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. A risk to the newborns/infants cannot be excluded.

Fertility

Animal data do not suggest an effect of treatment with dorzolamide on male and female fertility. Human data are lacking.

**4.7 Effects on ability to drive and use machines**

No studies on the effects on the ability to drive and use machines have been performed.

Possible adverse reactions such as dizziness and visual disturbances may affect the ability to drive and use machines (see section 4.8).

**4.8 Undesirable effects**

Dorzolamide containing eye drops was evaluated in more than 1400 individuals in controlled and uncontrolled clinical studies. In long term studies of 1108 patients treated with dorzolamide containing eye drops as monotherapy or as adjunctive therapy with an ophthalmic beta-blocker, the most frequent cause of discontinuation (approximately 3 %) from treatment with dorzolamide containing eye drops was medicinal product related ocular adverse reactions, primarily conjunctivitis and eyelid reactions.

The following adverse reactions have been reported either during clinical trials or during post- marketing experience with dorzolamide:

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Not known: (cannot be estimated from the available data)

Nervous system disorders

*Common:* headache

*Rare:* dizziness, paraesthesia

Eye disorders

*Very common:* burning and stinging

*Common:* superficial punctate keratitis, tearing, conjunctivitis, eyelid inflammation, eye itching, eyelid irritation, blurred vision

*Uncommon:* iridocyclitis

*Rare:* irritation including redness, pain, eyelid crusting, transient myopia (which resolved upon discontinuation of therapy), corneal oedema, ocular hypotony, choroidal detachment following filtration surgery

*Not known:* foreign body sensation in eye

Cardiac disorders

*Not known:* palpitations, tachycardia

Vascular disorders

*Not known:* hypertension

Respiratory, thoracic, and mediastinal disorders

*Rare:* epistaxis

*Not known:* dyspnoea

Gastrointestinal disorders

*Common:* nausea, bitter taste

*Rare:* throat irritation, dry mouth

Skin and subcutaneous tissue disorders

*Rare:* contact dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis

Renal and urinary disorders

*Rare:* urolithiasis

General disorders and administration site conditions

*Common:* asthenia/fatigue

*Rare:* hypersensitivity: signs and symptoms of local reactions (palpebral reactions) and systemic allergic reactions including angioedema, urticaria, pruritus, rash, shortness of breath, rarely bronchospasm

Investigations

Dorzolamide was not associated with clinically meaningful electrolyte disturbances.

Paediatric population

See section 5.1.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Lægemiddelstyrelsen

Axel Heides Gade 1

DK-2300 København S

Website: [www.meldenbivirkning.dk](http://www.meldenbivirkning.dk)

**4.9 Overdose**

Only limited information is available with regard to human overdose by accidental or deliberate ingestion of dorzolamide hydrochloride.

Symptoms

The following have been reported with

* oral ingestion: somnolence
* topical application: nausea, dizziness, headache, fatigue, abnormal dreams, and dysphagia.

Treatment

Treatment should be symptomatic and supportive. Electrolyte imbalance, development of an acidotic state, and possible central nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.

**4.10 Legal status**

B

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antiglaucoma preparations and miotics, carbonic anhydrase inhibitor. ATC code: S01EC03.

Mechanism of action

Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II) found primarily in red blood cells (RBCs) but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion. The result is a reduction in intra-ocular pressure (IOP).

Dorzolamid "Hexal" contains dorzolamide hydrochloride, a potent inhibitor of human carbonic anhydrase II. Following topical ocular administration, dorzolamide reduces elevated intra-ocular pressure, whether or not associated with glaucoma. Elevated intra-ocular pressure is a major risk factor in the pathogenesis of optic nerve damage and visual-field loss. Dorzolamide does not cause pupillary constriction and reduces intra-ocular pressure without adverse reactions such as night blindness or accommodative spasm. Dorzolamide has minimal or no effect on pulse rate or blood pressure.

Topically applied beta-adrenergic blocking agents also reduce IOP by decreasing aqueous humour secretion but by a different mechanism of action. Studies have shown that when dorzolamide is added to a topical beta-blocker, additional reduction in IOP is observed; this finding is consistent with the reported additive effects of beta-blockers and oral carbonic anhydrase inhibitors.

Clinical efficacy and safety

*Adult patients*

In patients with glaucoma or ocular hypertension, the efficacy of dorzolamide given t.i.d. (three times a day) as monotherapy (baseline IOP ≥ 23 mmHg) or given b.i.d. (two times a day) as adjunctive therapy while receiving ophthalmic beta-blockers (baseline IOP ≥ 22 mmHg) was demonstrated in large-scale clinical studies of up to one- year duration. The IOP-lowering effect of dorzolamide as monotherapy and as adjunctive therapy was demonstrated throughout the day and this effect was maintained during long-term administration. Efficacy during long-term monotherapy was similar to betaxolol and slightly less than timolol. When used as adjunctive therapy to ophthalmic beta-blockers, dorzolamide demonstrated additional IOP lowering similar to pilocarpine 2% q.i.d. (four times a day).

*Paediatric population*

A three month, double-masked, active-treatment controlled, multicentre study was undertaken in 184 (122 for dorzolamide) paediatric patients from one week of age to < 6 years of age with glaucoma or elevated intraocular pressure (baseline IOP > 22 mmHg) to assess the safety of dorzolamide when administered topically t.i.d.. Approximately half the patients in both treatment groups were diagnosed with congenital glaucoma; other common aetiologies were Sturge Weber syndrome, iridocorneal mesenchymal dysgenesis, aphakic patients. The distribution by age and treatments in the monotherapy phase was as follows:

|  |  |  |
| --- | --- | --- |
|  | Dorzolamide 2% | Timolol |
| Age cohort < 2 years | n=56Age range: 1 to 23 months | Timolol GS\* 0.25% n=27Age range: 0.25 to 22 months |
| Age cohort ≥ 2 - < 6 years | n=66Age range: 2 to 6 years | Timolol 0.5% n=35Age range: 2 to 6 years |

\* gel-forming solution

Across both age cohorts approximately 70 patients received treatment for at least 61 days and approximately 50 patients received 81-100 days of treatment.

If IOP was inadequately controlled on dorzolamide or timolol gel-forming solution monotherapy, a change was made to open-label therapy according to the following: 30 patients < 2 years were switched to concomitant therapy with timolol gel-forming solution 0.25% daily and dorzolamide 2% t.i.d.; 30 patients > 2 years were switched to 2% dorzolamide/0.5% timolol fixed combination b.i.d.. Overall, this study did not reveal additional safety concerns in paediatric patients: approximately 26% (20% in dorzolamide monotherapy) of paediatric patients were observed to experience drug related adverse effects, the majority of which were local, non serious ocular effects such as ocular burning and stinging, injection and eye pain. A small percentage <4%, was observed to have corneal oedema or haze. Local reactions appeared similar in frequency to comparator. In post marketing data, metabolic acidosis in the very young particularly with renal immaturity/impairment has been reported.

In post marketing data, metabolic acidosis in the very young particularly with renal immaturity/impairment has been reported.

Efficacy results in paediatric patients suggest that the mean IOP decrease observed in the dorzolamide group was comparable to the mean IOP decrease observed in the timolol group even if a slight numeric advantage was observed for timolol.

Longer-term efficacy studies (> 12 weeks) are not available.

**5.2 Pharmacokinetic properties**

Unlike oral carbonic anhydrase inhibitors, topical administration of dorzolamide hydrochloride allows for the active substance to exert its effects directly in the eye at substantially lower doses and therefore with less systemic exposure. In clinical trials with dorzolamide, this resulted in a reduction in IOP without the acid-base disturbances or alterations in electrolytes characteristic of oral carbonic anhydrase inhibitors.

When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, active substance and metabolite concentrations in red blood cells (RBCs) and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of selective binding to CA-II while extremely low concentrations of free active substance in plasma are maintained. The parent active substance forms a single N-desethyl metabolite that inhibits CA-II less potently than the parent active substance but also inhibits a less active isoenzyme (CA-I). The metabolite also accumulates in RBCs where it binds primarily to CA-I. Dorzolamide binds moderately to plasma proteins (approximately 33%). Dorzolamide is primarily excreted unchanged in the urine; the metabolite is also excreted in urine. After dosing ends, dorzolamide washes out of RBCs non-linearly, resulting in a rapid decline of active substance concentration initially, followed by a slower elimination phase with a half-life of about four months.

When dorzolamide was given orally to simulate the maximum systemic exposure after long-term topical ocular administration, steady state was reached within 13 weeks. At steady state, there was virtually no free active substance or metabolite in plasma; CA inhibition in RBCs was less than that anticipated to be necessary for a pharmacological effect on renal function or respiration. Similar pharmacokinetic results were observed after chronic, topical administration of dorzolamide.

However, some elderly patients with renal impairment (estimated CrCl 30-60 ml/min) had higher metabolite concentrations in RBCs, but no meaningful differences in carbonic anhydrase inhibition, and no clinically significant systemic adverse reactions were directly attributable to this finding.

**5.3 Preclinical safety data**

The main findings in animal studies with dorzolamide hydrochloride administered orally were related to the pharmacological effects of systemic carbonic anhydrase inhibition. Some of these findings were species-specific and/or were a result of metabolic acidosis. In rabbits given maternotoxic doses of dorzolamide associated with metabolic acidosis, malformation of the vertebral bodies were observed. In lactating rats, decreases in the body weight gain of offspring were observed. No adverse reactions upon fertility were observed in male and female rats given dorzolamide prior to and throughout mating.

In clinical studies, patients did not develop signs of metabolic acidosis or serum electrolyte changes that are indicative of systemic CA inhibition. Therefore, it is not expected that the effects noted in animal studies would be observed in patients receiving therapeutic doses of dorzolamide.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Mannitol

Sodium citrate

Hydroxyethylcellulose

Sodium hydroxide (for pH adjustment)

Benzalkonium chloride

Water for injections

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years.

After first opening: Use within 28 days.

**6.4 Special precautions for storage**

Store below 30 °C.

**6.5 Nature and contents of container**

White opaque MDPE bottle with a sealed LDPE dropper tip and a HDPE cap with tamper evident seal ring. Each bottle contains 5 ml of solution.

Pack sizes: 1×5 ml, 3×5 ml and 6×5 ml bottles.

Not all pack sizes may be marketed.

**6.6 Special precautions for disposal and other handling**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Hexal A/S

Edvard Thomsens Vej 14

2300 København S

**8. MARKETING AUTHORISATION NUMBER(S)**

61663

**9. DATE OF FIRST AUTHORISATION**

21 February 2020

**10. DATE OF REVISION OF THE TEXT**

9 April 2024